» Articles » PMID: 16981607

Validity of the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS)

Overview
Specialties Neurology
Psychology
Date 2006 Sep 20
PMID 16981607
Citations 254
Authors
Affiliations
Soon will be listed here.
Abstract

Cognitive impairment occurs in roughly 50% of patients with multiple sclerosis (MS). It is well known that processing speed and episodic memory deficits are the most common neuropsychological (NP) sequelae in this illness. Consensus has emerged about the specific tests that prove most helpful for routine monitoring of MS associated cognitive impairment. The purpose of this study was to examine the validity of the Minimal Assessment of Cognitive Function in MS (MACFIMS), a recommended battery based on the findings of an international conference held in 2001. We tested 291 MS patients and 56 healthy controls. Frequencies of impairment paralleled those reported in previous work for both individual cognitive domains and general impairment. All tests were impaired in the MS group, and distinguished relapsing-remitting (RR) from secondary progressive (SP) course. Principle components analysis showed a distinct episodic memory component. Most of the MACFIMS tests discriminated disabled from employed patients. However, in regression models accounting for all NP tests, those emphasizing verbal memory and executive function were most predictive of vocational status. We conclude that the MACFIMS is a valid approach to routine NP assessment of MS patients. Future work is planned to determine its psychometric properties in a longitudinal study.

Citing Articles

Eye-Tracking Metrics as a Digital Biomarker for Neurocognitive Disorders in Multiple Sclerosis: A Scoping Review.

Cecchetti S, Duchowski A, Cavallo M Brain Sci. 2025; 15(2).

PMID: 40002482 PMC: 11852410. DOI: 10.3390/brainsci15020149.


The Potential of Transcranial Direct Current Stimulation (tDCS) in Improving Quality of Life in Patients with Multiple Sclerosis: A Review and Discussion of Mechanisms of Action.

Chmiel J, Kurpas D, Stepien-Slodkowska M J Clin Med. 2025; 14(2).

PMID: 39860377 PMC: 11766291. DOI: 10.3390/jcm14020373.


A New Smartphone-Based Cognitive Screening Battery for Multiple Sclerosis (icognition): Validation Study.

Denissen S, Van Laethem D, Baijot J, Costers L, Descamps A, Van Remoortel A J Med Internet Res. 2025; 27:e53503.

PMID: 39832354 PMC: 11791456. DOI: 10.2196/53503.


Mapping cognitive dysfunction in relapsing multiple sclerosis with mild disability: A cross-sectional study from South India.

Nair S, Thulaseedharan J, Rajan N, Bava E, Nair G, Sundaram S Mult Scler J Exp Transl Clin. 2024; 10(4):20552173241304302.

PMID: 39676817 PMC: 11639032. DOI: 10.1177/20552173241304302.


In vivo evidence for cell body loss in cortical lesions in people with multiple sclerosis.

Krijnen E, Lee H, Noteboom S, Chiang F, Steenwijk M, Schoonheim M Ann Clin Transl Neurol. 2024; 12(1):4-16.

PMID: 39673156 PMC: 11752088. DOI: 10.1002/acn3.52237.